Apidra SoloStar Pens (100 Units/mL)
$95.00 – $410.00
Please Note:
As part of our commitment to safe and responsible use, you must be 19 years of age or older to enter this site. It is illegal for a person under 19 years of age to purchase or attempt to purchase anything from insulining.com; and it is illegal to purchase for minors. All sales are conditional on the purchaser and recipient being of legal age. For information about age restriction, please contact Us
Apidra SoloStar Pens (100 Units/mL) are a rapid-acting insulin (similar to Fiasp) that begins working 10 to 20 minutes after application. Like insulin produced in the body, it allows glucose into fat cells and muscles to have energy. In addition, it will block glucose from being released from the liver.
Apidra SoloStar Pens (100IU/ml injectable) are used to improve blood sugar levels in people with type 1 and type 2 diabetes. Fast-acting insulin effectively lowers blood sugar levels after meals and helps prevent severe diabetes complications.
Apidra is also available in vials and cartridges. Solostar pens and similar cartridges are available through the Apidra brand.
Diabetes medications or other long-acting insulin medications are typically prescribed with this medication. This insulin is to be injected subcutaneously (under the skin) by your nurse or doctor. You should exercise regularly, eat a healthy diet, and lose weight as part of your diabetes treatment.
Track your blood sugar levels regularly, and be sure to share them with your doctor so they can adjust your dosage accordingly. Your doctor may add other medications to your regimen such as Novolin and Ozempic to help better your diabetes management. Apidra SoloStar Pens (100 Units/mL)
Each ml contains 100 Units insulin glulisine (equivalent to 3.49 mg).
Each pen contains 3 ml of solution for injection, equivalent to 300 Units.
Insulin glulisine is produced by recombinant DNA technology in Escherichia coli.
For the full list of excipients, see section 6.1.
The primary activity of insulins and insulin analogues, including insulin glulisine, is regulation of glucose metabolism. Insulins lower blood glucose levels by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis in the adipocyte, inhibits proteolysis and enhances protein synthesis.
Studies in healthy volunteers and patients with diabetes demonstrated that insulin glulisine is more rapid in onset of action and of shorter duration of action than regular human insulin when given subcutaneously. When insulin glulisine is injected subcutaneously, the glucose lowering activity will begin within 10-20 minutes. After intravenous administration, a faster onset and shorter duration of action, as well as a greater peak response were observed as compared with subcutaneous administration. The glucose-lowering activities of insulin glulisine and regular human insulin are equipotent when administered by intravenous route.
One unit of insulin glulisine has the same glucose-lowering activity as one unit of regular human insulin.
| select quantity | 5pens, 10pens, 15pens, 20pens, 25pens |
|---|
Related products
Insulin
Diabetes Supplies
Diabetes Supplies
Diabetes Supplies